PB1871: HIGH RATES OF INFECTION AND RELATED MORALITY FROM VENETOCLAX THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE RETROSPECTIVE STUDY

Autor: Durga Chandran, Nicholas Viiala, Anne-Marie Watson, Lindsay Dunlop, Penelope Motum, Nagendraprasad Sungala, Heather Range, Bartlomiej Getta

Publikováno v: HemaSphere, Vol 7, p e4860556 (2023)

Externí odkaz: https://doaj.org/article/8c7fd27bd3e54ecebd3442630ace9619

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

Autor: Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin Filshie, Olatoyosi Odenike, Anne Marie Watson, Ravitharan Krishnadasan, Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Wei‐Han Cheng, Ying Zhou, David Hoffman, Jason G. Harb, Jalaja Potluri, Guillermo Garcia‐Manero

Publikováno v: American Journal of Hematology. 98:272-281

Patients with relapsed/refractory (R/R) higher-risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca66a377f5947c1895147bc041ed4ab1
https://doi.org/10.1002/ajh.26771

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

Autor: Mark Hertzberg, Maher K. Gandhi, Judith Trotman, Belinda Butcher, John Taper, Amanda Johnston, Devinder Gill, Shir-Jing Ho, Gavin Cull, Keith Fay, Geoff Chong, Andrew Grigg, Ian D. Lewis, Sam Milliken, William Renwick, Uwe Hahn, Robin Filshie, George Kannourakis, Anne-Marie Watson, Pauline Warburton, Andrew Wirth, John F. Seymour, Michael S. Hofman, Rodney J. Hicks

Publikováno v: Haematologica, Vol 102, Iss 2 (2017)

In the treatment of diffuse large B-cell lymphoma, a persistently positive [18F]fluorodeoxyglucose positron emission tomography (PET) scan typically carries a poor prognosis. In this prospective multi-center phase II study, we sought to establish whe

Externí odkaz: https://doaj.org/article/e5491b57b7b849d8b0c33b7f8a7661b1

ANZTCT Position Statement: COVID-19 Management in Haematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T cell Patients

Autor: Jacinta, Perram, Duncan, Purtill, Ashish, Bajel, Jason, Butler, Tracey, O'Brien, Benjamin, The, Nicole, Gilroy, Phoebe J, Ho, Richard, Doocey, Thomas, Hills, Travis, Perera, Genevieve, Douglas, Shanti, Ramachadran, Lynette, Chee, Judith, Trotman, Robert, Weinkove, Steven, Keogh, Chris, Fraser, Tara, Cochrane, Anne-Marie, Watson, Peter, Diamond, Maya, Latimer, Ian, Irving, Emily, Blyth, Chan, Cheah, Theresa, Cole, Sam, Milliken, Hung, Yang, Matthew, Greenwood, Peter, Bardy, Glen, Kennedy, Stephen, Larsen, Rachel, Conyers, Nada, Hamad

Publikováno v: Internal medicine journal.

Patients post haematopoietic stem cell transplant or CAR-T cell therapy face significant risk of morbidity and mortality from SARS-CoV19, due to their immunosuppressed state. As case numbers in Australia and New Zealand continue to rise, guidance on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::37e1d6f0c243caaea647135038b57fcd
https://pubmed.ncbi.nlm.nih.gov/36371767

Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy

Autor: Eunice S. Wang, Pau Montesinos, Mark D. Minden, Je-Hwan Lee, Michael Heuser, Tomoki Naoe, Wen-Chien Chou, Kamel Laribi, Jordi Esteve, Jessica K. Altman, Violaine Havelange, Anne-Marie Watson, Carlo Gambacorti-Passerini, Elzbieta Patkowska, Shufang Liu, Ruishan Wu, Nisha Philipose, Jason E. Hill, Stanley C. Gill, Elizabeth Shima Rich, Ramon V. Tiu

Publikováno v: Blood
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Blood, Vol. ., no.., p. . (2022)

Treatment results for patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated (FLT3mut+) acute myeloid leukemia (AML) ineligible for intensive chemotherapy are disappointing. This multicenter, open-label, phase 3 trial randomized (2:1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb5c44e8f06cb2ab0a2d252d525e8ede
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16756